India Pharma Outlook Team | Tuesday, 02 June 2026
Pfizer has launched its bispecific antibody therapy elranatamab in India, marking a significant step forward in the treatment landscape for patients with relapsed or refractory multiple myeloma.
The launch reinforces the company’s commitment to bringing innovative cancer therapies to the Indian market and improving access to advanced treatment options for patients facing difficult-to-treat blood cancers.
Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. While significant progress has been made in treating the disease over the past decade, many patients eventually experience a relapse and require additional treatment options. For such patients, finding effective multiple myeloma treatment after several rounds of therapy remains a major challenge.
Elranatamab is designed to help the body's immune system recognize and attack cancer cells more effectively. It belongs to a new class of medicines known as bispecific antibodies, which can bind to two different targets at the same time.
In this case, the therapy acts as a BCMA-targeted therapy, connecting cancer cells carrying B-cell maturation antigen (BCMA) with T-cells, a key component of the immune system. By bringing these cells together, the treatment helps activate the body's natural defense mechanisms against cancer.
Also Read: Little Angel IVF: Personalized Care at Delhi's Best IVF Centre
The therapy is administered through a subcutaneous injection and has shown encouraging results in clinical studies involving heavily pre-treated patients suffering from relapsed multiple myeloma and refractory multiple myeloma.
Researchers and oncologists view this treatment as an important advancement among emerging advanced cancer therapies because it offers a targeted approach while harnessing the power of the immune system.
The availability of Elranatamab in India is expected to provide doctors with another valuable treatment option for patients who have exhausted several existing therapies. It may also help address an important unmet medical need in the management of advanced multiple myeloma.
The launch comes as Pfizer continues to strengthen its presence in India’s healthcare sector by introducing innovative medicines across key therapeutic areas. The company has increasingly focused on ensuring that Indian patients gain faster access to breakthrough treatments that are already making an impact in global markets.
Healthcare experts believe that the introduction of advanced therapies such as Elranatamab reflects the growing importance of India in the global pharmaceutical landscape. As the country’s healthcare infrastructure continues to evolve, more patients are gaining access to cutting-edge treatments that were once available only in select international markets.
The launch also highlights the growing role of immunotherapy for cancer in modern oncology. Unlike traditional treatments that directly target cancer cells, immunotherapies work by enhancing the body's own ability to identify and destroy cancer. This approach has transformed treatment outcomes for several types of cancer and continues to be an area of significant research and investment.
Globally, Elranatamab has received recognition from regulatory authorities for its potential to address critical treatment gaps in relapsed or refractory multiple myeloma. Its introduction in India aligns with the broader trend of expanding access to innovative cancer medicines and accelerating oncology innovation worldwide.
With the launch of Elranatamab, oncologists across India gain access to an innovative treatment option that could help improve outcomes for patients facing limited alternatives. For individuals battling advanced multiple myeloma, the therapy represents a new source of hope and further strengthens Pfizer’s portfolio of Pfizer cancer drugs, underscoring the rapid progress being made in the fight against cancer.
.jpg)
